SEC
ROIV icon

Seven Eight Capital’s Roivant Sciences ROIV Stock Holding History

Seven Eight Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-84,422
Closed -$890K – 875
2024
Q1 		$890K Buy
+84,422
New +$910K 0.09% 326

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Seven Eight Capital's ROIV Position: Q2 2024 in Review

Seven Eight Capital sold out of Roivant Sciences (ROIV) in Q2 2024, closing a stake of 84,422 shares — an estimated $890K sold.

Seven Eight Capital first reported a position in ROIV in Q1 2024 and held it in 1 quarter. The position peaked at $890K in Q1 2024. 294 funds tracked by Wall St. Rank hold ROIV as of Q2 2024.

  • Seven Eight Capital reported no remaining Roivant Sciences position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 84,422 Roivant Sciences shares in Q2 2024, an estimated $890K.
  • Seven Eight Capital first reported a position in Roivant Sciences in Q1 2024 and held it in 1 quarter.
  • Seven Eight Capital's Roivant Sciences position peaked at $890K in Q1 2024.
  • 294 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.